Archive | November, 2017
PM 2 site 207

Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts.

Pol Arch Intern Med. 2017 Nov 30;127(11):785-789. doi: 10.20452/pamw.4123. Epub 2017 Oct 25. Hill KP, Palastro MD. Abstract Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession as well as legalization of medical and recreational cannabis. In this context, patients and their physicians have had an increasing number of conversations about […]

PM 2 site 207

Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD.

J Pharm Biomed Anal. 2017 Nov 28;150:25-32. doi: 10.1016/j.jpba.2017.11.054. [Epub ahead of print] Palazzoli F1, Citti C2, Licata M3, Vilella A4, Manca L4, Zoli M4, Vandelli MA5, Forni F5, Cannazza G6. Author information Abstract The investigation of the possible conversion of cannabidiol (CBD) into Δ9-tetrahydrocannabinol (THC) in vivo after oral administration of CBD is reported […]

De Gruyter Thumb site

Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry

Ahead of print Roberta Pacifici / Emilia Marchei / Francesco Salvatore / Luca Guandalini / Francesco Paolo Busardò / Simona Pichini Published Online: 2017-11-27 | DOI: 30,00 € / $42.00 / £23.00 GET ACCESS TO FULL TEXT Keywords: medical cannabis; stability; ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) References 1. Decreto 9 novembre 2015: Funzioni […]

PM 2 site 207

Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.

Psychopharmacology (Berl). 2017 Nov 25. doi: 10.1007/s00213-017-4793-4. [Epub ahead of print] Fattore L1, Piva A2, Zanda MT3, Fumagalli G2, Chiamulera C4. Author information Abstract RATIONALE: Clinical data with 3,4-methylenedioxymethamphetamine (MDMA) in post-traumatic stress disorder (PTSD) patients recently stimulated interest on the potential therapeutic use of psychedelics in disorders characterized by maladaptive memories, including substance use […]

PM 2 site 207

Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews.

Phytother Res. 2017 Nov 23. doi: 10.1002/ptr.5975. [Epub ahead of print] Schussel V1, Kenzo L1, Santos A1, Bueno J1, Yoshimura E1, de Oliveira Cruz Latorraca C2,3, Pachito DV2,3, Riera R1,3. Author information Abstract Nausea and vomiting are common and distressing adverse events of chemotherapy. This review focuses on the findings and quality of systematic reviews […]

PM 2 site 207

Alterations in Rat Accumbens Endocannabinoid and GABA Content during Fentanyl Treatment: The Role of Ghrelin.

Int J Mol Sci. 2017 Nov 22;18(11). pii: E2486. doi: 10.3390/ijms18112486. Sustkova-Fiserova M1, Charalambous C2, Havlickova T3, Lapka M4, Jerabek P5, Puskina N6, Syslova K7. Author information Abstract The opioid-induced rise of extracellular dopamine, endocannabinoid anandamide and γ-aminobutyric acid (GABA) concentrations triggered by opioids in the nucleus accumbens shell (NACSh) most likely participate in opioid […]

PM 2 site 207

Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans- tetrahydrocannabinol (delta-9-THC)] in Schedule II. Final rule.

Fed Regist. 2017 Nov 22;82(224):55504-6. Drug Enforcement Administration, Department of Justice.. Abstract This final rule adopts without changes an interim final rule with request for comments published in the Federal Register on March 23, 2017. On July 1, 2016, the U.S. Food and Drug Administration (FDA) approved a new drug application for Syndros, a drug […]

PM 2 site 207

Synthesis of Photoswitchable Δ9-Tetrahydrocannabinol Derivatives Enables Optical Control of Cannabinoid Receptor 1 Signaling.

J Am Chem Soc. 2017 Nov 21. doi: 10.1021/jacs.7b06456. [Epub ahead of print] Westphal M, Schafroth MA, Sarott R, Imhof M, Bold C, Leippe P, Dhopeshwarkar A, Grandner J, Katritch V, Mackie K, Trauner D, Carreira EM, Frank JA. Abstract The cannabinoid receptor 1 (CB1) is an inhibitory G protein-coupled receptor abundantly expressed in the […]

PM 2 site 207

Pharmacological Foundations of Cannabis Chemovars.

Planta Med. 2017 Nov 21. doi: 10.1055/s-0043-122240. [Epub ahead of print] Lewis MA1, Russo EB2, Smith KM1. Author information Abstract An advanced Mendelian Cannabis breeding program has been developed utilizing chemical markers to maximize the yield of phytocannabinoids and terpenoids with the aim to improve therapeutic efficacy and safety. Cannabis is often divided into several […]

PM 2 site 207

Simple and fast gas-chromatography mass spectrometry assay to assess delta 9-tetrahydrocannabinol and cannabidiol in dogs treated with medical cannabis for canine epilepsy.

Curr Pharm Biotechnol. 2017 Nov 21. doi: 10.2174/1389201018666171122115815. [Epub ahead of print] Rotolo MC1, Graziano S1, Pellegrini M1, Corlazzoli D2, Antinori L2, Porcarelli L2, Pichini S3. Author information Abstract BACKGROUND: To date, an increasing number of pet owners, especially in the USA, are using cannabis-derived products containing generally delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) to […]